Michael Gelband’s 10x Genomics TXG Stock Holding History

Michael Gelband’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$271K	Buy	+7,081	New	+$186K	﹤0.01%	1382
2025 Q4	–	Sell	-251,730	Closed	-$2.94M	–	2083
2025 Q3	$2.94M	Buy	+251,730	New	+$3.28M	0.03%	597
2025 Q1	–	Sell	-188,430	Closed	-$2.71M	–	2004
2024 Q4	$2.71M	Sell	188,430 -366,528	-66%	-$5.78M	0.02%	607
2024 Q3	$12.5M	Buy	554,958 +265,747	+92%	+$5.49M	0.08%	196
2024 Q2	$5.63M	Buy	289,211 +123,479	+75%	+$3.23M	0.04%	370
2024 Q1	$6.22M	Buy	+165,732	New	+$7.28M	0.05%	329
2023 Q3	–	Sell	-107,718	Closed	-$6.01M	–	2162
2023 Q2	$6.01M	Buy	+107,718	New	+$5.83M	0.05%	384
2023 Q1	–	Sell	-39,250	Closed	-$1.43M	–	2140
2022 Q4	$1.43M	Buy	+39,250	New	+$1.28M	0.02%	787
2022 Q2	–	Sell	-19,563	Closed	-$1.49M	–	2468
2022 Q1	$1.49M	Buy	19,563 +14,942	+323%	+$1.31M	0.02%	922
2021 Q4	$688K	Buy	+4,621	New	+$708K	0.01%	1252
2021 Q3	–	Sell	-5,466	Closed	-$1.07M	–	2645
2021 Q2	$1.07M	Buy	+5,466	New	+$989K	0.01%	980
2021 Q1	–	Sell	-22,326	Closed	-$3.16M	–	2624
2020 Q4	$3.16M	Sell	22,326 -31,255	-58%	-$4.54M	0.03%	382
2020 Q3	$6.68M	Buy	+53,581	New	+$5.62M	0.13%	138

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's TXG Position: Q2 2026 in Review

Michael Gelband opened a new position in 10x Genomics (TXG) in Q2 2026: 7,081 shares worth $271K. The stake represents ﹤0.01% of the portfolio and ranks #1382 among its holdings. This is a return to the name: Michael Gelband previously reported a position in TXG as recently as Q3 2025.

Michael Gelband first reported a position in TXG in Q3 2020 and has held it in 13 quarters since. The position peaked at $12.5M in Q3 2024. 389 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Michael Gelband held 7,081 shares of 10x Genomics worth $271K as of Q2 2026.
10x Genomics was a new Michael Gelband position in Q2 2026.
10x Genomics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1382 holding.
Michael Gelband first reported a position in 10x Genomics in Q3 2020 and has held it in 13 quarters since.
Michael Gelband's 10x Genomics position peaked at $12.5M in Q3 2024.
389 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.